Candidemia Clinical Trial
Official title:
Prospective Collection and Testing of Un-Spiked and Candida-Spiked Fresh Whole Blood Specimens From Patients Who Have Been Referred For a Diagnostic Blood Culture
The purpose of this study is to validate clinical performance (i.e. estimated sensitivity and specificity) of the T2 Candida test on the T2 DX Instrument compared to blood culture results and/or known Candida positive status of prospectively collected and contrived (i.e. Candida-spiked) clinical specimens.
This study will prospectively collect and analyze whole blood T2 clinical research specimens
and concomitant blood culture specimens from patients who have been referred for a blood
culture per routine standard of care. Additional analysis of blinded, contrived (i.e.
Candida spiked and un-spiked whole blood) specimens will be completed by study sites to
augment the analysis of Candida positive blood specimens prospectively obtained from the
study population.
The clinical performance of the T2 Candida test on the T2 Dx Instrument will be evaluated by
calculating the:
- Estimated clinical specificity of the T2Candida test results compared to Candida
negative blood culture results in prospectively collected specimens, and the
- Estimated sensitivity of the T2 Candida test results compared to the known Candida
positive status or Candida positive blood culture status of contrived specimens that
have been spiked at clinically relevant concentrations of the target organisms and,
where detected, to Candida positive blood culture results in prospectively collected
clinical specimens.
;
Observational Model: Case-Only, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01982071 -
A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia
|
Phase 4 | |
| Completed |
NCT02244606 -
Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis
|
Phase 2 | |
| Completed |
NCT02163889 -
Serial Therapeutic and Antifungal Monitoring Protocol
|
||
| Recruiting |
NCT01438216 -
Anidulafungin Pharmacokinetics in Intensive Care Unit Patients
|
N/A | |
| Not yet recruiting |
NCT01249313 -
Risk Factor and Outcome of Candidemia
|
N/A | |
| Completed |
NCT00940017 -
A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects
|
Phase 4 | |
| Terminated |
NCT01213823 -
Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins
|
Phase 4 | |
| Completed |
NCT00105144 -
Study of Micafungin in Patients With Invasive Candidiasis or Candidemia
|
Phase 3 | |
| Completed |
NCT03667690 -
Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
|
Phase 3 | |
| Completed |
NCT03604705 -
An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia
|
Phase 2 | |
| Completed |
NCT00607763 -
Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
|
Phase 1 | |
| Completed |
NCT00608335 -
Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
|
Phase 1 | |
| Recruiting |
NCT04147975 -
Assessment of Assay for Rapid Identification of Bloodstream Infections From Whole Blood
|
||
| Completed |
NCT01734525 -
Negative Beta Glucan in ICU Patients
|
Phase 4 | |
| Withdrawn |
NCT01622595 -
UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients
|
N/A | |
| Completed |
NCT03363841 -
Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)
|
Phase 3 | |
| Completed |
NCT03799172 -
Echinocandins Versus Azoles for Candidemia Treatment
|
||
| Completed |
NCT01406093 -
Early- and Late-onset Candidemia
|
N/A | |
| Completed |
NCT00670657 -
CRITIC - Treatment of Candidemia and Invasive Candidiasis
|
Phase 4 | |
| Completed |
NCT00113191 -
Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants
|
N/A |